<DOC>
	<DOCNO>NCT00517712</DOCNO>
	<brief_summary>There limit data use arsenic trioxide newly diagnose patient acute promyelocytic leukemia . The use arsenic trioxide limit relapsed patient mainly superior efficacy ATRA primary therapy newly diagnose APML . Though early study Niu et al show 72 % remission rate 11 newly diagnose patient , role arsenic trioxide primary therapy limit hepatic toxicity see study . Studies centre show remission rate 70-75 % newly diagnose patient acute promyelocytic leukemia . There major toxicity see related administration arsenic trioxide . Follow data patient continue show long term remission rate 70 % . These remission rate similar data available patient acute promyelocytic leukemia treat ATRA . Lu et al study 19 patient treated oral arsenic ( Tetra-arsenic tetra-sulfide ) wherein 84 % achieve hematological remission disease free survival 76 % 3 year . Studies group use arsenic trioxide alone combination ATRA show similar remission rate . Arsenic trioxide primary therapy patient newly diagnose acute promyelocytic leukemia attractive treatment option develop country mainly low cost involve along favorable toxicity profile . However long term remission data still available ideal course duration treatment still need define . This multi-center study aim clarify efficacy agent treatment newly diagnose case acute promyelocytic leukemia study optimal maintenance regimen .</brief_summary>
	<brief_title>Single Agent Arsenic Trioxide Treatment Newly Diagnosed Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>This multicenter trial study clinical molecular response among patient newly diagnose acute promyelocytic leukemia ( APL ) fulfill inclusion exclusion criterion . Patients include trial diagnose Acute Promyelocytic Leukemia morphologically FAB criterion . This sufficient initiate therapy arsenic trioxide ( ATO ) diagnosis confirm use either Fluorescent situ hybridization ( FISH ) ( 15 ; 17 ) reverse transcriptase polymerase chain reaction assay ( RT-PCR ) PML-RARalpha transcript within 7 day inclusion study . All patient would absence study receive palliative therapy due lack resource support standard chemotherapy . Women pregnant consider study . Treatment Protocol : All patient include study initiate treatment ATO . Arsenic tri-oxide ( 10 mg/10ml ) dilute 500 ml Dextrose Saline ( glass bottle use ) infuse intravenously 3 - 4 hour day . No premedication require prior administration drug . The dosage schedule administration follow : Adults : 10 mg day Children adult &lt; 45kg : 0.15 mg/kg/day ( maximum dose = 10mg ) day The total course therapy follow : Induction therapy : Induction therapy continue till ANC &gt; 1.5 x 10e9/L Platelet count &gt; 100 x 10e9/L along absence abnormal promyelocytes peripheral smear 2 consecutive occasion . Once achieve , bone marrow study do assess remission . If bone marrow show &lt; 5 % myeloblast promyelocytes along normocellular mildly hypocellular marrow , arsenic stop . If CR , arsenic continue additional 2 week repeat bone marrow do confirm CR . Arsenic tri-oxide give maximum 60 day follow patient would consider non-responder/partial responder exclude treatment . If bone marrow show &lt; 5 % blast promyelocytes 60 day peripheral blood count criterion CR fulfil , patient still continue study regimen . Consolidation therapy : All patient achieve CR receive consolidation therapy period 28 day interval 4 week achieve hematological CR . The dosage mode administration similar schedule follow induction . Maintenance therapy : All patient molecular CR end consolidation therapy randomize 2 group : Group A : This group receive 12 month maintenance therapy . ATO administer 10 day every month period 12 month . Group B : This group receive 6 month maintenance therapy . ATO administer 10 day every month period 6 month . All patient continue RT-PCR positive end consolidation randomize continue receive course maintenance treatment . Subsequent therapy individualize base molecular monitoring result . A total 400 patient recruited time initiation study . We expect loss follow up/treatment failure/death approximately 10 % study population hence 360 patient randomize final 2 arm study ie maintenance therapy 12 month versus 6 month complete consolidation therapy . Patients CNS disease treat therapeutic Radiotherapy intrathecal chemotherapy use Cytosine , Hydrocortisone Methotrexate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Patients include trial diagnose Acute Promyelocytic Leukemia morphologically FAB criterion . This sufficient initiate therapy arsenic trioxide diagnosis confirm use either Fluorescent situ hybridization ( FISH ) ( 15 ; 17 ) reverse transcriptase polymerase chain reaction assay ( RTPCR ) PMLRARalpha transcript within 7 day inclusion study . All patient would absence study receive palliative therapy due lack resource support standard chemotherapy . Women pregnant Patients acute promyelocytic leukemia find standard karyotyping/ FISH/RTPCR ( 11 ; 17 ) ( 5 ; 17 ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Acute promyelocytic leukemia</keyword>
	<keyword>Arsenic trioxide</keyword>
	<keyword>Molecular remission</keyword>
	<keyword>Toxicity profile</keyword>
	<keyword>Maintenance therapy</keyword>
</DOC>